BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1156 related articles for article (PubMed ID: 32832992)

  • 1. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
    Chen G; Huang AC; Zhang W; Zhang G; Wu M; Xu W; Yu Z; Yang J; Wang B; Sun H; Xia H; Man Q; Zhong W; Antelo LF; Wu B; Xiong X; Liu X; Guan L; Li T; Liu S; Yang R; Lu Y; Dong L; McGettigan S; Somasundaram R; Radhakrishnan R; Mills G; Lu Y; Kim J; Chen YH; Dong H; Zhao Y; Karakousis GC; Mitchell TC; Schuchter LM; Herlyn M; Wherry EJ; Xu X; Guo W
    Nature; 2018 Aug; 560(7718):382-386. PubMed ID: 30089911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
    Yao X; Tu Y; Xu Y; Guo Y; Yao F; Zhang X
    J Cell Mol Med; 2020 Sep; 24(17):9560-9573. PubMed ID: 32672418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
    Kim DH; Kim H; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Pack CG; Jung MK; Han B; Kim K; Kim WS; Nam SJ; Choi CM; Yun M; Lee JC; Rho JK
    Exp Mol Med; 2019 Aug; 51(8):1-13. PubMed ID: 31399559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+ T-cell activity and promotes immune escape.
    Yang J; Chen J; Liang H; Yu Y
    Cancer Sci; 2022 Sep; 113(9):3044-3054. PubMed ID: 35598173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of exosomal PD-L1 in tumor progression and immunotherapy.
    Xie F; Xu M; Lu J; Mao L; Wang S
    Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer cells promote CD169
    Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
    Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer cells synergistically defend against CD8
    Li D; Zhou X; Xu W; Chen Y; Mu C; Zhao X; Yang T; Wang G; Wei L; Ma B
    Cancer Med; 2023 Aug; 12(15):16405-16415. PubMed ID: 37501397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis.
    Wang G; Xie L; Li B; Sang W; Yan J; Li J; Tian H; Li W; Zhang Z; Tian Y; Dai Y
    Nat Commun; 2021 Sep; 12(1):5733. PubMed ID: 34593794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets.
    Liang B; Hu X; Ding Y; Liu M
    J Cell Physiol; 2021 Jun; 236(6):4138-4151. PubMed ID: 33275291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
    Qiu Y; Yang Y; Yang R; Liu C; Hsu JM; Jiang Z; Sun L; Wei Y; Li CW; Yu D; Zhang J; Hung MC
    Oncogene; 2021 Aug; 40(31):4992-5001. PubMed ID: 34172932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8
    Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T
    J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phototheranostic Metal-Phenolic Networks with Antiexosomal PD-L1 Enhanced Ferroptosis for Synergistic Immunotherapy.
    Xie L; Li J; Wang G; Sang W; Xu M; Li W; Yan J; Li B; Zhang Z; Zhao Q; Yuan Z; Fan Q; Dai Y
    J Am Chem Soc; 2022 Jan; 144(2):787-797. PubMed ID: 34985903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression.
    Zhang W; Zhong W; Wang B; Yang J; Yang J; Yu Z; Qin Z; Shi A; Xu W; Zheng C; Schuchter LM; Karakousis GC; Mitchell TC; Amaravadi R; Herlyn M; Dong H; Gimotty PA; Daaboul G; Xu X; Guo W
    Dev Cell; 2022 Feb; 57(3):329-343.e7. PubMed ID: 35085484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Significance of PD-L1
    Theodoraki MN; Yerneni SS; Hoffmann TK; Gooding WE; Whiteside TL
    Clin Cancer Res; 2018 Feb; 24(4):896-905. PubMed ID: 29233903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional CD3
    Lv S; Wang S; Qiao G; Wang X; Zhou X; Yan F; Li Y; Wang S; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Breast Cancer; 2019 Oct; 19(5):e617-e623. PubMed ID: 31101455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrin α2 promotes immune escape in non-small-cell lung cancer by enhancing PD-L1 expression in exosomes to inhibit CD8 + T-cell activity.
    Jing H; Meng M; Ye M; Liu S; Cao X; Li K; Liu Y; Zhang J; Wu Y
    J Investig Med; 2024 Jan; 72(1):57-66. PubMed ID: 37804164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.